#cancerImmunotherapy
LightNews LightNews
drjonlim.bsky.social
What a hero - congratulations John (and team!)! Prof John Haanen is a role model to so many of us 🏆.

@nkinl.bsky.social
#CancerImmunotherapy
#CancerImmunology #CellTherapy
November 26, 2024 at 3:17 PM
sophiawongyn.bsky.social
Awesome review on combination strategies with ICB #CancerImmunotherapy #ImmuneCheckpoint
pamsharmamdphd.bsky.social Padmanee (Pam) Sharma, MD, PhD @pamsharmamdphd.bsky.social · Nov 25
www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 26, 2024 at 4:16 AM
drjonlim.bsky.social
Yay 🙌! Our #CellTherapy for solid cancers community is growing here 🦋.

Welcome 👋
@drbetofmdphd.bsky.social 🇺🇸
@sklobuch.bsky.social 🇳🇱
@sophiawongyn.bsky.social 🇸🇬

#CancerImmunotherapy
December 7, 2024 at 3:34 PM
castltrastondrs.medsky.network
#MedSky🧪#Cancerimmunotherapy #Cancerbiology CD8+ #Tcells are end effectors of #cancerimmunity. Most forms of effective #cancerimmunotherapy involve CD8+ T cell effector function.
Hypoxia
October 11, 2023 at 11:08 AM
gmj-georgia.bsky.social
🔬 mRNA cancer vaccines use an unexpected immune backup system that scientists didn't know about until now. This discovery could lead to…

#Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcology #Vaccinedevelopment

#Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcolog…
mRNA Vaccines' Hidden Immune Backup System
🔬 mRNA cancer vaccines use an unexpected immune backup system that scientists didn't know about until now. This discovery could lead to… #Cancerimmunotherapy #Immunemechanism #MRNAvaccine #Precisiononcology #Vaccinedevelopment
news.gmj.ge
October 1, 2026 at 9:26 AM
drjonlim.bsky.social
#Immuno25

That’s a wrap 🙌! Such a fantastic day getting to discuss all about #CancerImmunotherapy, alongside fellow enthusiasts & friends.

@zaydtippu.bsky.social
@annaob.bsky.social
@beckilee.bsky.social
@ikshinchin1.bsky.social
@mcrcnews.bsky.social
January 24, 2025 at 7:33 PM
drjonlim.bsky.social
Almost 2️⃣ years in…

Our MANIFEST AGM convened scientists, clinicians, patient partners & industry. Keynotes from Prof Levesque & Prof Rattray + Prof Turajlić setting the course ahead.

Big thank you to all for continuing to believe in the vision; to tackle the hard questions in #CancerImmunotherapy.
June 7, 2026 at 7:08 AM
drjonlim.bsky.social
The final results of the practice-changing clinical trial in first line treatment of patients with advanced #melanoma: CheckMate 067.

💊 Combination of anti-PD1 + anti-CTLA-4.

#CancerImmunotherapy
#ImmuneCheckpoint
nejm.org NEJM.org @nejm.org · Jan 5
Among patients with advanced melanoma, median overall survival was 72 months with nivolumab plus ipilimumab and was 37 months with nivolumab alone, as compared with 20 months with ipilimumab alone. Full CheckMate 067 trial results: nej.md/4dUqm0g

#MedSky
The New England Journal of Medicine Nivolumab plus Ipilimumab in Advanced Melanoma A PLAIN LANGUAGE SUMMARY Visual representation of an immune checkpoint inhibitor. Read the full Plain Language Summary at NEJM.org.
January 5, 2025 at 9:27 PM
elviraforte.bsky.social
The preprint detailing the results of the #SchmidtCenter Cancer Immunotherapy Machine Learning Competition is online!

@broadinstitute.org #MachineLearning #CancerImmunotherapy #ComputationalBiology #PerturbSeq #AI4Science #VirtualCell

www.biorxiv.org/content/10.6...
May 22, 2026 at 10:43 PM
miguel-miranda.bsky.social
Great recent review on next-gen combination strategies to enhance immune checkpoint therapy! #CancerImmunotherapy
pamsharmamdphd.bsky.social Padmanee (Pam) Sharma, MD, PhD @pamsharmamdphd.bsky.social · Nov 25
www.nature.com/articles/s41...

Sharing our latest review article to highlight the importance of appropriately developing combination strategies for immune checkpoint therapy. Grateful for working with 3 brilliant scientists: Sangeeta Goswami, Kristen Pauken & Linghua Wang
Next-generation combination approaches for immune checkpoint therapy - Nature Immunology
In this Review, Sharma and colleagues describe the current landscape of combination therapies and discuss requirements for the development of effective combination strategies.
www.nature.com
November 26, 2024 at 5:30 AM
castltrastondrs.medsky.network
#Medsky🧪 #oncosky ICIs are widely used for #cancerimmunotherapy but only a fraction of patients respond & gut bacteria impact the efficacy of ICIs in fighting tumors outside of the gut. Certain strains of commensal #gutbacteria promote antitumor responses to ICIs …
labwaggoner.bsky.social Waggoner Lab @labwaggoner.bsky.social · Feb 4
The gut microbiome and cancer response to immune checkpoint inhibitors
www.jci.org/articles/vie...
Review @jclinical-invest.bsky.social
February 4, 2025 at 7:36 PM
castltrastondrs.medsky.network
#Medsky🧪 #IDsky #oncosky #immunosky #publichealth The advent of mRNA vaccines has revolutionized prophylactic & therapeutic strategies across multiple disease areas, from #infectiousdiseases to #cancerimmunotherapy. While highly effective in protecting against #
June 23, 2025 at 1:25 PM
oncodaily.bsky.social
Trispecific antibodies for enhanced cancer immunotherapy

oncodaily.com/blog/cancer-...

#Cancer #CancerImmunotherapy #FDA #Oncodaily #Oncology #TrispecuficAntibodies #Health #Medicine
Trispecific antibodies for enhanced cancer immunotherapy - OncoDaily
Trispecific antibodies for enhanced cancer immunotherapy / Antonio Tapia-Galisteo, cancer, cancer immunotherapy, FDA, Hung Trinh, Laura Sanz, Luis
oncodaily.com
January 23, 2025 at 5:39 AM
shihcheng.bsky.social
CD70-targeted iPSC-derived CAR-NK cells show >90% tumor cytotoxicity, offering universal therapy for cancer! #CancerImmunotherapy PMID:39793572, Cell Rep Med 2025 https://www.cell.com/cell-reports-medicine/fulltext/S2666-3791(24)00660-8?rss=yes&utm_source=dlvr.it&utm_medium=twitter 🧪
February 24, 2025 at 7:40 AM
drjonlim.bsky.social
🗓️ Save the date!

Join us on 24 & 27 January 2025 in Manchester for everything #CancerImmunotherapy: ranging from principles of immunology to biomarkers, checkpoint blockade, novel/advanced therapies & toxicity management.

🗳️ To register:
www.eventbrite.co.uk/e/the-cancer...

@mcrcnews.bsky.social
November 23, 2024 at 4:47 PM
jem.org
Microbiota-centred interventions to boost immune checkpoint blockade therapies. New review from Andrew Almonte, Simon Thomas, and Laurence Zitvogel @gustaveroussy.fr: rupress.org/jem/article/...

#Immunotherapy #Microbiome #CancerResearch #CancerImmunotherapy #MicrobiomeMatters #GutHealth
April 29, 2025 at 1:33 PM
castltrastondrs.medsky.network
MedSky🧪 #Immunotherapy #Gutmicrobiome & #Cancerimmunotherapy The #gutmicrobiota influences anti-tumor #immunity & can induce or inhibit response to #immunecheckpointinhibitors
abstract
March 28, 2024 at 10:55 AM
piermorgante.bsky.social
Join our next #RSCDesktopSeminar with Xinyue Liu and @wanglabuiuc.bsky.social presenting their #Biomaterials research! Chaired by yours truly 😀

Register today and join the live Q&A ➡️ rsc.li/4wLO1Jk

#Bioengineering #Hydrogels #CancerImmunotherapy #ChemSky
The logo of the RSC Desktop Seminar featuring Biomaterials research presented by Emerging Investigators in the Americas
July 16, 2026 at 12:24 PM
castltrastondrs.medsky.network
#Medsky🧪 #IDSky #immunosky #Oncosky #publichealth The study explores the long-term implications of #COVID19pandemic on #cancerimmunotherapy.
🔑
-Persistent 🦠 spike protein exposure can sustain inflammatory pathways, disrupting the tumor microenvironment & compromising #immunotherapy efficacy.
Post COVID-19 pandemic Inflammatory Insights into Cancer: Consequences for immunotherapy
The COVID-19 pandemic has reshaped the landscape of global health, revealing novel interactions between infectious diseases and chronic conditions suc…
www.sciencedirect.com
December 7, 2025 at 7:48 AM
natrevcancer.nature.com
Melero&Co discuss the crucial role of conventional type 1 dendritic cells in cross-presenting antigens to prime CD8+ T cells to mount anti-tumour immunity and highlight how this can be exploited for #CancerImmunotherapy
@unav.edu
📖 ⬇️
Cross-priming in cancer immunology and immunotherapy - Nature Reviews Cancer
www.nature.com
February 11, 2025 at 4:04 PM
imtadvances.bsky.social
Temporal control of cytokine production is lost in 2nd-gen CAR-T cells, says Patel et al. This could be key to understanding their efficacy and toxicity in cancer immunotherapy. 🧬

🔗 https://bit.ly/4lOLicw
##CancerImmunotherapy
July 17, 2025 at 2:25 PM
drjonlim.bsky.social
Already planning your calendar for 2️⃣ 0️⃣ 2️⃣ 5️⃣ ?

🐝 Why not visit us in Manchester & join us in our flagship #CancerImmunotherapy event. Programme now finalised & speakers confirmed 🤩!

🗓️ 2 days: 24 & 27 Jan 2025 (hybrid)

To register (discount code - IMMUNO10):
www.eventbrite.co.uk/e/the-cancer...
December 23, 2024 at 7:53 PM
cshasia.bsky.social
#CSHAsia #CancerImmunotherapy #Immunology #CancerResearch
Join us this September for the CSHA Symposium on Cancer Immunotherapy!

👉 Submit your registration: www.csh-asia.org?content/2986
August 21, 2026 at 5:30 AM
juditarvelund.bsky.social
ACIR has joined #bluesky 🥳
Make sure to give them a follow if you are interested in #cancerimmunotherapy research! 👇🏼
acir-org.bsky.social ACIR @acir-org.bsky.social · Nov 20
Our team just wrapped up #SITC24! We're thrilled to share insights from 16 groundbreaking talks on the latest in #immunotherapy. 🧬✨ Stay ahead in the field—click here to catch all the updates! bit.ly/4<a href="/hashtag/SITC2024" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#SITC2024ITC2024
SITC - 39th Annual Meeting 2024
This week’s extensive special feature covers select talks from the SITC - 39th Annual Meeting 2024 in Houston, TX.
bit.ly
November 20, 2024 at 4:59 PM
acir-org.bsky.social
Translation dysregulation may serve as a new source for identifying cancer-associated antigens, and may also help to predict responses to checkpoint blockade bit.ly/3E4OMY8 #CheckpointBlockade #CancerImmunotherapy @wellerchen.bsky.social @Samuels-lab.bsky.social  @yardenasamuels.bsky.social
April 2, 2025 at 3:55 PM